Design and rationale of a retrospective clinical effectiveness study of aldosterone antagonist therapy in patients with heart failure

American Heart Journal

Volumn 163, Issue 6, 2012, Pages

  Curtis, Lesley H ^a,b   Mi, Xiaojuan ^a   Qualls, Laura G ^a   Hammill, Bradley G ^a   Hammill, Stephen C ^c   Heidenreich, Paul A ^d   Masoudi, Frederick A ^e   Setoguchi, Soko ^a,b   Hernandez, Adrian F ^a,b   Fonarow, Gregg C ^f  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MAYO CLINIC   (United States)

^d VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; DIURETIC AGENT; WARFARIN;

AGED; ARTICLE; CLINICAL ASSESSMENT; CLINICAL DECISION MAKING; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; CONTROLLED STUDY; DISEASE REGISTRY; DRUG EFFICACY; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITAL PATIENT; HOSPITAL READMISSION; HUMAN; HYPERKALEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICARE; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SAMPLE SIZE; STUDY DESIGN;

EID: 84862571101     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2012.03.007     Document Type: Article

References (24)

1. Lloyd-Jones D, Adams R, Carnethon M, et al. Heart disease and stroke statistics-2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2009;119:e21-e181.
2. Centers for Medicare & Medicaid Services. Medicare & Medicaid Statistical Supplement, 2010 Edition. http://www.cms.gov/ MedicareMedicaidStatSupp/09-2010.asp. Last accessed May 12, 2011.
3. Curtis LH, Greiner MA, Hammill BG, et al. Early and long-term outcomes of heart failure in elderly persons, 2001-2005. Arch Intern Med 2008;168:2481-8.
4. Cherubini A, Oristrell J, Pla X, et al. The persistent exclusion of older patients from ongoing clinical trials regarding heart failure. Arch Intern Med 2011;171:550-6.
5. Shah KB, Rao K, Sawyer R, et al. The adequacy of laboratory monitoring in patients treated with spironolactone for congestive heart failure. J Am Coll Cardiol 2005;46:845-9. (Pubitemid 41224809)
6. Institute of Medicine. Initial national priorities for comparative effectiveness research. Washington, DC: National Academies Press; 2009.
7. Hunt SA; American College of Cardiology, American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure). J Am Coll Cardiol 2005;46:e1-e82.
8. Albert NM, Yancy CW, Liang L, et al. Use of aldosterone antagonists in heart failure. JAMA 2009;302:1658-65.
9. Fonarow GC, Yancy CW, Albert NM, et al. Heart failure care in the outpatient cardiology practice setting: findings from IMPROVE HF. Circ Heart Fail 2008;1:98-106.
10. Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004;351:543-51. (Pubitemid 39025171)
11. Ensuring integrity in comparative effectiveness research: accentuate the negative. PLoS Med 2009;6:e1000152.
12. Vandenbroucke JP, von Elm E, Altman DG, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology 2007;18:805-35. (Pubitemid 350295185)
13. Hong Y, LaBresh KA. Overview of the American Heart Association "Get with the Guidelines" programs: coronary heart disease, stroke, and heart failure. Crit Pathw Cardiol 2006;5:179-86. (Pubitemid 44912337)
14. Hammill BG, Hernandez AF, Peterson ED, et al. Linking inpatient clinical registry data to Medicare claims data using indirect identifiers. Am Heart J 2009;157:995-1000.
15. Ray WA. Evaluating medication effects outside of clinical trials: newuser designs. Am J Epidemiol 2003;158:915-20. (Pubitemid 37323253)
16. Keenan PS, Normand SL, Lin Z, et al. An administrative claims measure suitable for profiling hospital performance on the basis of 30-day all-cause readmission rates among patients with heart failure. Circ Cardiovasc Qual Outcomes 2008;1:29-37.
17. Krumholz HM, Wang Y, Mattera JA, et al. An administrative claims model suitable for profiling hospital performance based on 30-day mortality rates among patients with heart failure. Circulation 2006;113:1693-701.
18. Butler J, Arbogast PG, Daugherty J, et al. Outpatient utilization of angiotensin-converting enzyme inhibitors among heart failure patients after hospital discharge. J Am Coll Cardiol 2004;43:2036-43. (Pubitemid 38686798)
19. Gray RJ. A class of K-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16:1141-54.
20. Roger VL, Go AS, Lloyd-Jones DM, et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 2011;123:e18-e209.
21. Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17. (Pubitemid 29407370)
22. Zannad F, McMurray JJ, Krum H, et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011;364:11-21.
23. Vasan RS, Larson MG, Benjamin EJ, et al. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction: prevalence and mortality in a population-based cohort. J Am Coll Cardiol 1999;33:1948-55.
24. Curtis LH, Greiner MA, Hammill BG, et al. Representativeness of a national heart failure quality-of-care registry: comparison of OPTIMIZE-HF and non-OPTIMIZE-HF Medicare patients. Circ Cardiovasc Qual Outcomes 2009;2:377-84.